|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Cancer Vaccines and Cell Therapies - Technical Know How Needs Translation Into Clinical and Commercial Rewards
Datamonitor, April 2005, Pages: 203
Outline of this report
-Examination of cancer vaccine pipeline with in-depth clinical and commercial profiles of Phase III candidates.
-Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of Phase III agents to 2014
-Analysis of the cancer vaccine market, identifying developmental, manufacturing, logistical, regulatory and commercialization issues
Insight and commentary from qualitative interviews with oncology opinion leaders in the US and Europe
Highlights and Analysis
Given the relative immaturity and lack of precedence of the cancer vaccine market, an entirely new set of clinical and strategic issues has been brought to light. Significant hurdles need to be overcome, both on a local and international level before successful commercialization of a cancer vaccine can be realized.
Cancer vaccines will complement current treatment approaches, rather than serve as a replacement. If the full potential of cancer vaccines is realized, the need for multiple-lines of treatment may be eliminated, ultimately driving the cost of oncology care down.
The majority of the cancer vaccine pipeline constitutes off-the-shelf vaccines rather than personalized or cell-based formulations. Although the former are capable of mass manufacture, the latter have shown greater clinical benefit, but encompass a more complex and expensive formulation. It is unclear which class will reach the market first.
Reasons to Purchase
-Identify the key cancer vaccines and cell therapies in the current pipeline based on sales forecasts to 2014 and the reports drug assessments
-Assess opportunities and risks for cancer
-vaccines and cell therapies within the oncology market
-Optimize development and commercialization of cancer vaccines by improving strategic planning
Customers who bought this item also bought
Cancer Cell Therapy Markets
Cancer Vaccine Developments to 2013 + Cancer Vaccine Tracker
Pipeline Insight: Therapeutic Cancer Vaccines - A Turbulent Path from Bench to Bedside
Cancer Vaccines and Tumor Immunity
Cancer Vaccine Developments to 2013
Cancer Vaccines: Measuring Market Potential
Analytical Tool - Cancer Vaccines
Competitive Outlook on Non-Antibody Based Cancer Vaccines
Analytical Tool - Competitive Outlook on Cancer Vaccines
Drug Delivery in Cancer - Technologies, Markets and Companies
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Pipeline And Commercial Insight: Influenza Vaccines - Pandemic Threat Revitalizes The Sector
|
|
|
|
